Ardelyx, Inc. (ARDX)
ARDX Stock Price Chart
Explore Ardelyx, Inc. interactive price chart. Choose custom timeframes to analyze ARDX price movements and trends.
ARDX Company Profile
Discover essential business fundamentals and corporate details for Ardelyx, Inc. (ARDX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Jun 2014
Employees
395.00
Website
https://www.ardelyx.comCEO
Michael G. Raab
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
ARDX Financial Timeline
Browse a chronological timeline of Ardelyx, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 18 Feb 2026
Upcoming earnings on 30 Oct 2025
EPS estimate is -$0.07, while revenue estimate is $100.44M.
Earnings released on 4 Aug 2025
EPS came in at -$0.08 surpassing the estimated -$0.13 by +38.46%, while revenue for the quarter reached $97.66M , beating expectations by +3.21%.
Earnings released on 1 May 2025
EPS came in at -$0.17 falling short of the estimated -$0.10 by -70.00%, while revenue for the quarter reached $74.11M , missing expectations by -6.71%.
Earnings released on 20 Feb 2025
EPS came in at $0.02 matching the estimated $0.02, while revenue for the quarter reached $116.13M , beating expectations by +55.79%.
Earnings released on 31 Oct 2024
EPS came in at -$0.00 surpassing the estimated -$0.05 by +93.14%, while revenue for the quarter reached $98.24M , missing expectations by -9.51%.
Earnings released on 1 Aug 2024
EPS came in at -$0.07 surpassing the estimated -$0.10 by +30.00%, while revenue for the quarter reached $73.22M , beating expectations by +33.08%.
Earnings released on 2 May 2024
EPS came in at -$0.11 surpassing the estimated -$0.13 by +15.38%, while revenue for the quarter reached $46.02M , beating expectations by +26.44%.
Earnings released on 22 Feb 2024
EPS came in at -$0.12 falling short of the estimated -$0.09 by -33.33%, while revenue for the quarter reached $34.36M , beating expectations by +0.39%.
Earnings released on 31 Oct 2023
EPS came in at $0.03 surpassing the estimated -$0.11 by +127.27%, while revenue for the quarter reached $56.39M , beating expectations by +79.65%.
Earnings released on 2 Aug 2023
EPS came in at -$0.08 surpassing the estimated -$0.12 by +33.33%, while revenue for the quarter reached $22.33M , beating expectations by +46.25%.
Earnings released on 3 May 2023
EPS came in at -$0.13 falling short of the estimated -$0.11 by -18.18%, while revenue for the quarter reached $11.37M , beating expectations by +7.25%.
Earnings released on 2 Mar 2023
EPS came in at $0.06 surpassing the estimated $0.00 by +6.09K%, while revenue for the quarter reached $44.18M , beating expectations by +90.63%.
Earnings released on 3 Nov 2022
EPS came in at -$0.14 surpassing the estimated -$0.17 by +17.65%, while revenue for the quarter reached $4.99M , beating expectations by +27.14%.
Earnings released on 4 Aug 2022
EPS came in at -$0.19 matching the estimated -$0.19, while revenue for the quarter reached $2.53M , beating expectations by +13.73%.
Earnings released on 5 May 2022
EPS came in at -$0.21 falling short of the estimated -$0.20 by -5.00%, while revenue for the quarter reached $468.00K , missing expectations by -46.51%.
Earnings released on 28 Feb 2022
EPS came in at -$0.31 falling short of the estimated -$0.25 by -24.00%, while revenue for the quarter reached $1.03M , beating expectations by +17.53%.
Earnings released on 12 Nov 2021
EPS came in at -$0.42 falling short of the estimated -$0.34 by -23.53%, while revenue for the quarter reached $1.17M , beating expectations by +67.57%.
Earnings released on 13 Aug 2021
EPS came in at -$0.45 falling short of the estimated -$0.36 by -25.00%, while revenue for the quarter reached $1.31M , meeting expectations.
Stock split effective on 20 Jul 2021
Shares were split 4 : 1 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 6 May 2021
EPS came in at -$0.34 falling short of the estimated -$0.32 by -6.25%, while revenue for the quarter reached $6.58M , beating expectations by +3.13%.
Earnings released on 8 Mar 2021
EPS came in at -$0.32 falling short of the estimated -$0.26 by -23.08%, while revenue for the quarter reached $1.81M .
Earnings released on 5 Nov 2020
EPS came in at -$0.20 surpassing the estimated -$0.28 by +28.57%, while revenue for the quarter reached $2.71M , missing expectations by -28.57%.
ARDX Stock Performance
Access detailed ARDX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.